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During the last decades, several improvements in treating gynecological malignancies have been achieved. In particular, target
therapies, mostly monoclonal antibodies, have emerged as an attractive option for the treatment of these malignancies. In fact,
various molecular-targeted agents have been developed for a variety of malignancies with the objective to interfere with a precise
tumor associated receptor, essential for cancer cell survival or proliferation, blocking its function, of the cancer cells. Alternatively,
monoclonal antibodies have been developed to block immune suppression or enhance functions of immune eﬀector cells. So
far, several monoclonal antibodies have been tested for clinical eﬃcacy for the treatment of gynecological cancers. Antibodies
against Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) have been used in diﬀerent
neoplasms such as ovarian and cervical cancer. Catumazumab, a bivalent antibody against CD3 and EpCAM, is eﬀective in the
treatment of neoplastic ascites. Other antibodies are peculiar for speciﬁc cancer-associated antigen such as Oregovomab against
CA125 or Farletuzumab against the folate receptor. Here we describe the preclinical and clinical experience gained up to now with
monoclonal antibodies in tumors of the female genital tract and trace future therapeutic and research venues.
1.Introduction
Despite the improvement achieved during the last decades
in gynecological cancer treatment, most of these patients,
especially women aﬀected by ovarian cancer, are at great
risk of recurrence and emerging drug resistance. Therefore,
novel approaches are required to improve outcomes for
gynecological cancer patients. Recently, various molecular-
targeted agents have been developed and used in the man-
agement of a variety of malignancies, including ovarian,
cervical, and endometrial cancers. The therapeutic beneﬁts
of targeted clinical interventions, with increased selectivity
and fewer adverse eﬀects, hold great promises in the treat-
ment of solid malignancies, both as single therapy and in
combination.Inparticular,MonoclonalAntibodies(MoAbs)
represent the majority of target therapies which have been
investigated and employed in clinical settings so far. These
immunological reagents recognize molecular targets whose
expression is tumor associated or/and are essential for the
cancer cell survival and proliferation such as the Vascular
Endothelial Growth Factor (VEGF), the Epidermal Growth
Factor Receptor (EGFR) family, CA125, MUC1, and other
signaling pathways which are aberrant in tumor tissue
(EpCAM). Also, the targeting of immune cells by MoAbs
h a sb e e np r o v e dt ob ea ne ﬃcacious strategy to modulate
immune system functions (anti-CTLA-4, anti-CD3, anti-
CD40). To date, several MoAbs have been approved for the
treatment of colorectal, breast, head and neck, nonsmall cell
lung, and renal cell cancer (Table 1). Encouraging results
have being achieved also in gynecological tumors. Here, we
review the most promising MoAbs that are under early or
advanced investigation for the treatment of neoplasms of the
lower genital tract.2 Clinical and Developmental Immunology
2. Rationaleof Monoclonal Antibodiesin
Cancer Treatment
Signiﬁcant advances in gynecological cancer management
have been recently achieved, including interesting progresses
in surgical, chemotherapeutic, and concurrent chemo-ra-
dioterapeutic settings. However, more eﬀective, speciﬁc, and
less toxic approaches need to be investigated. Based on
the promising results of preclinical studies, various targeted
therapies are currently being evaluated in cancer patients.
One of the most promising approaches, that may improve
patient outcome, is the use of MoAbs. The use of MoAbs
in cancer treatment is focused on the idea of selectively tar-
geting tumor cells that express tumor-associated antigen [1],
with the aim to speciﬁcally antagonize receptor signaling
pathways, which are essential for proliferation, survival, and
migration of tumor cells. Thus, MoAbs oﬀer increasingly
customized solutions based on the targeting of multiple
speciﬁc pathways essential for cancer development and
metastasis by attacking targeted tumor cells. Furthermore,
the high speciﬁcity of the target reduces cytotoxic side eﬀects
on normal tissue, seen with traditional chemotherapeutic
agents, and should permit the maintenance of a high quality
of life. The ﬁrst experience of MoAb administration in
cancer patient was carried out in a patient aﬀected by
non-Hodgkin’s lymphoma [2]. Since then, several MoAbs
against cancer-associated antigens have been developed and
MoAbs have rapidly become one of the biggest classes of
new drugs approved for the treatment of cancer (Table 1).
To date, several ongoing trials are investigating the role of
MoAbs in ovarian, cervical, and endometrial cancer (Tables
2–5). In some cases, MoAbs have already demonstrated
favorableclinicaloutcomesinphaseI/IIstudiesandarebeing
investigated further in phase III trials. However, further
investigations for most of these molecules are required to
establish a convincing proof of safety and eﬃcacy of them
in gynecological tumors.
3. Monoclonal Antibodies:
Mechanisms of Action
MoAbs are antibodies produced by hybridoma cells. In
the sixties the conventional route to derive MoAbs was to
immunize mice. It took 10 years to be translated to the
patient with MoAb muromonab, a murine-derived antibody
for acute organ rejection approved by FDA in 1986 [3]. Re-
cently, recombinant engineering techniques permitted the
construction of MoAbs with possible variation in size, va-
lence, conﬁguration, and eﬀectors functions. This tech-
nology results in the development of fragment, chimeric,
humanized, and fully humanized MoAbs.
MoAb therapy consists in targeting speciﬁc extracellular/
cell-surface pathways in order to destroy malignant tumor
cells and prevent tumor growth by blocking speciﬁc cell
receptors.
Binding speciﬁcity and selective molecular targeting are
the major advantages of this approach. The general mech-
anism mediated by MoAb administration is the speciﬁc
recognition of an antigen selectively expressed by tumor cells
and the generation of immune-complexed cells, that can
activate distinct immune mechanisms mainly mediated by
the Fc region of the MoAb. Increased uptake by antigen
presenting cells, NK activation, and induction of ADCC
are the eﬀects described. Moreover, the engineering of the
Fc domain permits to increase aﬃnity towards speciﬁc
FcRs, potentiating the action of speciﬁc innate immune
cells. This is the case of MoAbs directed against antigens
that are homogenously overexpressed by cancer cells such
as MUC1 and CA125. The identiﬁcation of molecules
that have a key role in tumor progression and immune
modulation has led to the generation of immune reagents
that combine speciﬁcity to the ability to exert a biological
function on the target cell. Three main approaches can be
identiﬁed.
(1) MoAbs Recognizing Speciﬁc Tumor-Associated Receptors.
Tumor cells display speciﬁc receptors that are rare or absent
on the surfaces of healthy cells, and which are responsible
for activating cellular signal transduction pathways that
cause the unregulated growth and division of the tumor
cell. Speciﬁc targeting of these receptors can block tumor-
associated transduction pathways, reducing tumorigenicity
and invasiveness. MoAbs, such as trastuzumab, act through
this mechanism [4].
(2) MoAbs Targeting Tumor Promoting Molecules. During
tumor transformation several tumor promoting molecules
are produced by the cancer cells, suppressing and subvert-
ing the function of immune system. The administration
of MoAbs targeting such molecules can interfere in the
binding of the molecule to its receptor or/and increases the
clearence of these soluble factors, thus reducing tumor cell
growth. Bevacizumab, the MoAb against VEGF molecule, is
a paradigmatic example. In fact, binding of bevacizumab to
VEGF blocks VEGF binding to its receptor [5].
(3) MoAbs Targeting Immune Eﬀector Cells. The targeting of
immune cells can be achieved by the employment of MoAbs
speciﬁc for surface receptors that can have suppressing or
activating function. The CTLA-4 molecule expressed by
eﬀector cells exerts an inhibitory function and the functional
blocking of this molecule is being investigated in clinical
trials [6].
On the other hand, targeting of activating molecules,
such as CD3, is a strategy to enhance the functions of
immune eﬀector cells. The strategy utilized is to generate
a bispeciﬁc antibody able to recognize simultaneously a
relevant tumor antigen and an immune-speciﬁc activating
molecule. In this way, the antibody combines the speciﬁc
recognition of the target cells to the selective activation
of the immune eﬀector cell, bringing the two cells phys-
ically close, thus making easier the immune recognition.
Catumaxomab, a bispeciﬁc antibody recognizing EpCAM
and the CD3 molecule, is a prototype of such reagents
[6].Clinical and Developmental Immunology 3
Table 1: FDA-approved MoAbs for cancer patients.
Monoclonal antibody Target Approved cancer patients Mode Year of introduction
Rituximab CD20 Non-Hodgkin Lymphoma Chimeric IgG1 1997
Trastuzumab ErbB2 Breast Humanized IgG1 1998
Gemtuzumab-ozogamicin CD33 Acute myeloid leukemia Humanized IgG4 + ozogamicin 2000
Alemtuzumab CD52 Chronic lymphocytic leukemia Humanized IgG1 2001
Ibritumomab tiuxetan CD20 Non-Hodgkin’s lymphoma Murine IgG1+Yttrium90 2002
I-Tositumomab CD20 Non-Hodgkin’s lymphoma Murine IgG2a+iodine-131 2003
Cetuximab EGFR Colorectal Head/Neck Chimeric IgG1 2003
Bevacizumab VEGF Colorectal Humanized IgG1 2004
Panitumumab EGFR Colorectal Humanized IgG2 2006
Ofatumumab CD20 Chronic Lymphocytic Leukemia Human IgG1 2009
Ipilimumab CTLA-4 Late stage melanoma Human IgG1 2011
4. Monaclonal AntibodiesinOvarianCancer
In contrast to hematological malignancies and certain solid
tumors such as breast and colorectal cancer, MoAbs have
not been completely proven to be clinically eﬀective in the
treatment of ovarian cancer, although encouraging results
arebeingachieving.Currently,themostlyinvestigatedtargets
in ovarian cancer are (VEGF) and (EGFR) family members
(EGFR1, EGFR2/ErbB2).
Other tumor-associated antigens, such as the adhesion
molecule EpCAM, the epithelial mucins CA125 and MUC1,
and the Folate Receptor as well as molecules expressed by
immunecellssuchasCD3andCTLA-4areunderevaluation.
4.1. Vascular Endothelial Growth Factor-Targeted
Therapy: Bevacizumab
4.1.1. Vascular Endothelial Growth Factor (VEGF). VEGF,
also known as Vascular Permeability Factor, is a potent an-
giogenetic cytokine that induces mitosis and regulates the
permeability of endothelial cells.
Overexpression of VEGF correlates with increased mi-
crovascular density, cancer recurrence, and decreased sur-
vival in several neoplasms, including most gynaecological
tumors [7–13].
In women with ovarian cancer, high serum levels of
VEGF are found to be an independent risk factor for ascites,
advanced-stage disease, undiﬀerentiated histology, number
of metastasis, and decreased survival [9–11]. In ovarian
carcinoma there is suggestive evidence showing that higher
VEGF levels are associated with aggressive clinical behavior.
4.1.2. Bevacizumab. Bevacizumab represents the most inves-
tigated target therapy in ovarian neoplasia. It is a humanized
monoclonal antibody directed against the VEGF ligand
able to inhibit the formation of new blood vessels and to
decrease the diameter, density, and permeability of blood
vessels, resulting in a normalization of tumor vascularization
[14, 15]. Moreover it has been shown that VEGF acts as
immunosuppressive factor, contributing to the skewing of
the antitumor immune response and the development of
immunosuppressive microenvironment [16]. Randomized
trials in solid tumors have shown that the addition of be-
vacizumab to standard chemotherapeutic regimens results
in statistically signiﬁcant improvements in progression-free
survival (PFS) and, in some cases, in overall survival (OS)
[17–19]. Currently, bevacizumab has not been approved for
any malignancy of the female genital tract, although initial
encouraging data have been achieved for these types of
neoplasms, especially for ovarian cancer. Up to day, several
investigators have explored bevacizumab as a single agent
or in combination with chemotherapy in the management
of ovarian cancer [20]. Both alone or in combination with
traditional drugs, it has shown interesting levels of activity
and provided clinically meaningful results in patients with
recurrent ovarian disease [21–30]. Furthermore, it has also
been used as a palliative treatment of symptomatic ascites
[21, 23, 31–35]. In one of these kinds of experience [35],
immunological analyses after intraperitoneal bevacizumab
administration showed a concomitant increase in number
a n df u n c t i o no fC D 8 +Te ﬀector cells and a decrease of
circulating regulatory T cells (Treg) cells, similarly to what
observed in ovarian cancer patients undergoing to debulking
surgery and radiotherapy [36]. These eﬀects observed on
the immune performance of the patient can be due to
the pleiotropic function of VEGF that can directly acts as
immunosuppressive molecule on the immune microenvi-
ronment [16]. The most considerable results concerning the
role of bevacizumab on progressive disease in ovarian cancer
patientscanbederivedfromrecentanalysisoftwocompleted
randomized phase III trials: the GOG 218 [37]a n dI C O N
7[ 38] .T h e s ew e r ep e r f o r m e du s i n gb e v a c i z u m a bi nn e w l y
diagnosed advanced stage ovarian cancer, in association with
standard chemotherapy. The GOG 218 [37] is a three-arm
placebocontrolledtrial:1873patientshavebeenrandomized
to iv paclitaxel-carboplatin for 6 cycles with or without be-
vacizumab in the latter ﬁve followed by placebo or additional
48 weeks of maintenance bevacizumab (15mg/kg every 3
weeks). Preliminary data, initially presented at the 2010
meeting for the American Society of Clinical Oncology
(ASCO), showed a signiﬁcant improvement in PFS in pa-
tients treated with concurrent and maintenance beva-
cizumab, 14.1 months versus 10.3 months in the placebo
arm. Relative to arm 1 of the trial, the hazard ratio for ﬁrst4 Clinical and Developmental Immunology
progression in the maintenance arm of the trial was 0.717
(95% CI: 0.625–0.824, P<0.0001). OS data are not yet
mature.
The ICON7 trial [38] is a two-arm, non-placebo con-
trolled trial comparing carboplatin-paclitaxel (6 cycles) ver-
sus carboplatin-paclitaxel-bevacizumab (7,5mg/kg) every
threeweeksfor6cycles,followedby12cyclesofmaintenance
bevacizumabordiseaseprogression,whicheveroccurredear-
lier. Data from this trial were presented at the 2010 meeting
of the European Society of Medical Oncology (ESMO). A
total of 1528 women were randomized from 263 centers.
Compared to the control arm, the hazard ratio for disease
progressioninthebevacizumabarmwas0.81(95%CI:0.70–
0.94, P<0.0041).
In the setting of recurrent ovarian cancer, of great
importance will be the mature results of AURELIA trial [39]
(so far open to accrual), that is investigating the association
of bevacizumab with platinum compounds both in platinum
sensitive, and in platinum resistant patients.
The timing of bevacizumab administration during plat-
inum-based regimens is believed to be a crucial point in
the design of eﬃcacious therapy in patients with recurrent
disease.
The two ongoing phase III trials GOG213 [40]a n d
OCEANS [41] take in consideration such parameter. Both
trials target patients with recurrent disease: the former plans
the administration of carboplatin and paclitaxel with or
without bevacizumab in platinum sensitive relapsed OC
patients, while in the latter carboplatin and gemcitabine with
or without bevacizumab in recurrent disease, respectively.
In conclusion, up to now data arising from phase III
trials show beneﬁts in terms of Disease Free Survival (DFS).
The beneﬁt of bevacizumab on OS requires to be better
investigated.
4.2. Epidermal Growth Factor Receptor Targeted Therapy:
Trastuzumab, Cetuximab and Pertuzumab
4.2.1. Epidermal Growth Factor Receptor (EGFR) Family.
EGFR family is a receptor family composed of four struc-
turally similar tyrosine kinase receptors, ErbB1/HER1 (com-
monly referred to as EGFR), ErbB2/HER2 (commonly
referred to as HER2), ErbB3/HER3, and ErbB4/HER4 [42].
They are expressed on the apical surface of epithelial cells.
After binding with its ligand, the EGFR undergoes dimer-
ization followed by tyrosine autophosphorylation, leading
to the activation of EGFR signaling. Activation of down-
stream signaling pathways is known to mediate a variety
of cellular responses, including cancer cell proliferation,
survival, motility, and invasion. Moreover, as these receptors
are overexpressed in many solid tumors, they have been
recognized as promising targets for cancer therapy. Several
MoAbs against the extracellular domain of EGFRs have been
developed with the peculiar ability to block signaling of
the receptor upon binding. Trastuzumab and Pertuzumab,
directed against HER2 molecule and cetuximab (directed
towards HER1), are in clinical use for several solid cancers.
Also they have been evaluated in the framework of treatment
regimens for ovarian cancer.
4.2.2. Trastuzumab (Anti-HER2). Trastuzumab is a human-
izedMoAbspeciﬁcfortheextracellulardomainofHER2that
has been selected for its ability to block HER2 signaling after
binding to the receptor HER2 is overexpressed in approxi-
mately 30% of breast cancers and is associated with a more
severeprognosis [43,44].Trastuzumabis currentlyapproved
for refractory breast cancers positive HER2/neu either as a
single agent or in combination with paclitaxel. To evaluate
the therapeutic potential of trastuzumab in ovarian cancer,
several preclinical studies have been conducted using HER2-
expressing ovarian cancer cells [45, 46].
At least ﬁve potential extracellular and intracellular anti-
tumor mechanisms of trastuzumab have been identiﬁed in
the preclinical setting. These include activation of antibody-
dependent cellular cytotoxicity, inhibition of the activatory
extracellulardomaincleavage,abrogationofintracellularsig-
naling, reduction of angiogenesis, and decreased DNA repair
[47]. Recently, also cellular adaptive immune system has
been proposed to play a crucial role in trastuzumab clinical
eﬃcacy [48]. The overall results of these synergistic eﬀects
lead to tumor cell stasis and/or death.
On the basis of the promising results obtained in breast
cancer patients [49] and the results of preclinical studies
in ovarian cancer models [45, 46], the ﬁrst phase II study
evaluating the eﬃcacy of trastuzumab in patients with
recurrent ovarian cancers overexpressing HER2 was carried
out in 2003 [50]. Forty-one women aﬀected by recurrent
or refractory ovarian or primary peritoneal carcinoma with
2+ or 3+ HER2 overexpression were enrolled. Patients with-
out progressive disease or grade 3-4 toxicities could continue
the treatment indeﬁnitely. Patients with stable or responding
disease were oﬀered, after 8 weeks of treatment, to increase
the weekly dose up to 4mg/kg until disease progression.
Median treatment duration was 8 weeks (range 2 to 104
weeks) and median progression-free interval was 2 months.
Patients were analysed for the presence of soluble extracel-
lular domain of HER2 and antibodies against trastuzumab.
Circulating extracellular domain of HER2 increased during
treatment in 8 of 24 evaluable patients. This immunological
outcome was not associated to clinical outcome. No increase
of anti-trastuzumab antibodies was observed. Although
trastuzumab was well tolerated with common side eﬀects
of anemia, gastrointestinal disturbance, neuropathy, and
fatigue, the overall response rate in these patients was only
7% with a median progression-free interval of 2 months.
Interestingly, among patients with recurrent ovarian cancer
who were screened for participation in the trial, only 11.4%
were judged to have overexpression of HER2. On the
basis of these results, the GOG was unable to recommend
trastuzumab in OC.
4.2.3. Pertuzumab (Anti-HER2). Pertuzumab is a recombi-
nant, humanized monoclonal antibody binding to the HER2
dimerization domain, sterically blocking the binding pocket
required for receptor dimerization with its partner receptors,
thus inhibiting the signaling cascades [51]. Pertuzumab
binding to HER2 induces activation of ADCC eﬀects but
does not block the truncation of HER2 in the same way as
trastuzumab binding does [52]. In a phase II study of 123Clinical and Developmental Immunology 5
Table 2: Ongoing treatment studies evaluating MoAb treatment in ovarian cancer patients.
Protocol
number
Disease
stage Target therapy Treatment Study phase PI
NCT00565851
(GOG-213) Recurrent Bevacizumab
Arm I:
Phase III Coleman RL, MD Carboplatin + Paclitaxel/Docetaxel
every 3 weeks
Arm II:
Carboplatin + Paclitaxel/Docetaxel +
Bevacizumab every 3 weeks
NCT00483782
(ICON 7) Primary Bevacizumab
Arm I:
Phase III Perren TJ, MD Carboplatin + Paclitaxel for 6 cycles
Arm II:
C a r b o p l a t i n+P a c l i t a x e l+B e vf o r6
c y c l e s+B e vf o r1 2c y c l e s
NCT00849667 Recurrent Farletuzumab
Arm I:
Phase III Morphotek, Inc
Carboplatin + Taxane + Farletuzumab
1.25mg/kg
Arm II:
Carboplatin + Taxane + Farletuzumab
2.5mg/kg
Arm III:
Carboplatin + Taxane + Placebo
NCT00951496 Primary Bevacizumab
Arm I:
Phase III Joan L. Walker, MD
Carboplatin + Paclitaxel + bevacizumab
for 6 cycles + bev until
progression/recurrence
Arm II:
Carboplatin + Paclitaxel + bevacizumab
for 6 cycles
Arm III:
Carboplatin + Paclitaxel + bevacizumab
for 6 cycles
NCT00976911 Primary Bevacizumab
Arm I:
Phase III Hoﬀmann-La Roche Topotecan + Paclitaxel + liposomal
doxorubicin
Arm II:
Bevacizumab + Topotecan + Paclitaxel
+ liposomal doxorubicin
NCT01081262 Primary Bevacizumab
bevacizumab
Phase III Martin E. Gore, MD
capecitabine
carboplatin
oxaliplatin
paclitaxel
Procedure: quality-of-life assessment
NCT01167712 Primary Bevacizumab Arm I: Carboplatin + Paclitaxel Phase III John K. Chan, MD
Arm II: Carboplatin + Paclitaxel
NCT01239732 Primary Bevacizumab Arm I: Carboplatin + Bevacizumab +
Paclitaxel
Phase III Hoﬀmann-La Roche
recurrentovariancancerpatients,55patientsincohort1and
62 in cohort 2 were evaluable for eﬃcacy [53]. The patients
in cohort 1 received a loading dose of 840mg of pertuzumab
intravenously followed by 420mg every 3wk; the patients in
cohort 2 received 1050mg every 3wk and showed an overall
response rate of 4.3%. The main adverse events observed
were diarrhea and asymptomatic left ventricular ejection
fraction decreases of <50%.
Combination therapy of pertuzumab with gemcitabine
was tested in a randomized phase II trial in 130 patients with6 Clinical and Developmental Immunology
Table 3: Ongoing treatment studies evaluating EGFR MoAbs in cervical cancer patients.
Protocol
number Disease stage Target therapy Adjuvant treatment Study phase PI
NCT00803062 Stage IVb/ Bevacizumab Cisplatin/topotecan
hydrochloride/paclitaxel
Phase III Krishnansu Tewari, MD
recurrent/persistent
NCT00548418 Recurrent/Persistent Bevacizumab Topotecan/cisplatin Phase II Janet S Rader, MD
Table 4: Ongoing treatment studies evaluating VEGF MoAbs in cervical cancer patients.
Protocol
number Disease stage Target therapy Adjuvant treatment Study phase PI
NCT00292955 locally
advanced/metastatic Cetuximab Cisplatin + radiotherapy Phase II Linda R.
Duska, M.D
NCT00104910 Stages Ib-IVA Cetuximab Cisplatin + radiotherapy +
brachitherapy Phase I John H.
Farley, MD
NCT00997009 Advanced/Recurrent Cetuximab Paclitaxel + carboplatin Phase II Sandro
Pignata, MD
NCT00957411 Stages IB-IIIB Cetuximab Cisplatin Phase II Susan Scholl,
MD
NCT01158248 Stages Ib-III Panitumumab Cisplatin + Radiotherapy +
brachitherapy Phase II Alain Zeimet
NCT01301612 Adenocarcinoma Nimotuzumab Cisplatin + Radiotherapy +
brachitherapy Phase II Sergio Lago
platinum-resistant ovarian, fallopian tube, or primary peri-
toneal cancer [54]. The patients were randomly assigned
to gemcitabine (800mg/m2 on days 1 and 8 of a 21-day
cycle) plus either placebo or pertuzumab (840mg loading
dose followed by 420mg every 3wks) and showed objective
response rates of 13.8% and 4.6%, respectively. Therefore,
pertuzumab was able to signiﬁcantly increase the eﬀect of
gemcitabine.
4.2.4. Cetuximab (Anti-HER1). Cetuximab is a chimeric
MoAb that binds to the extracellular domain of EGFR
(HER1).
It was developed to target the EGFR, thus preventing
ligand activation of EGFR [55, 56]. In preclinical studies,
cetuximab has been able to repress the growth of cultured
A431 tumour cells and xenografts that expressed high levels
of EGFR [57, 58]. In other solid tumours, cetuximab has
shown to enhance the eﬀects of diﬀerent chemotherapeutic
agents, including platinum [59, 60].
Based on these data, cetuximab was administered in
combination with carboplatin to 28 patients with relapsed
platinum-sensitive ovarian cancer. Cetuximab was infused at
an initial dose of 400mg/m2 on cycle 1, day 1, followed by
weekly infusions of 250mg/m2. Carboplatin (AUC 6) was
administered IV on day 1 at 3-week intervals. The treat-
ment was continued until disease progression or prohibiting
toxicities. Twenty-six (92.9%) out of 28 patients were found
to have EGFR+ tumours, whereas the remnant 2 patients
(7.1%) had EGFR-tumours. Clinical response was reported
forEGFR+tumours:in9patients(34.6%)aclinicalresponse
was observed (3 (11.5%) Complete Response (CR); 6 (23%)
Partial Response (PR)). Three patients (11.5%) had a
progressive disease and the remaining 8 patients (30.8%)
showed stable disease. The median PFS was over 9.4 months.
Some grade 3 and three grade 4 toxicities were experienced
but only three could be attributed to cetuximab.
In the same year, cetuximab combined with paclitaxel
plus carboplatin was experimented as initial treatment in
40 advanced-stage ovarian, primary peritoneal, or fallop-
ian tube cancer patients [61]. Thirty-eight out of the 40
participants had previously undergone abdominal surgery,
whereas the remaining two patients were approached with
neoadjuvant chemotherapy. The administration schedule
consisted in an initial dose of cetuximab 400mg/m2 IV,
followed by weekly infusions of cetuximab 250mg/m2,p l u s
Paclitaxel 175mg/m2 and carboplatin (AUC 6) administered
IV at 3-week intervals. Patients obtaining a complete clinical
response after 6 cycles were eligible for a maintenance
treatment with weekly cetuximab, for 6 months or until
progressive disease or major toxicity. Thirty out of 40
patients completed all six cycles of chemotherapy and were
evaluable for response: 21 of them achieved a complete
clinical response. Twenty patients entered the cetuximab
maintenance phase, but only ten completed all six cycles
of cetuximab. Ten patients discontinued because of toxicity
(5), progressive disease (2), grade 3-sinusitis (1), ﬂuid
accumulation (1), or other (1). The overall median time
of PFS in the initial population was 14.4 months, with a
third of the population with progressive disease after 24
months. Eleven (27.5%) out of 40 patients experienced at
least one adverse event to cetuximab, with one case of grade
3-4 toxicity, whereas seven patients (17.5%) experienced
toxicitytopaclitaxel(threegrade3-4toxicity).Consequently,
although the combination of cetuximab, paclitaxel, andClinical and Developmental Immunology 7
Table 5: Ongoing treatment studies evaluating MoAbs in endometrial cancer patients.
Protocol
number Disease stage Target therapy Adjuvant
treatment Study phase PI
NCT01010126 Endometrial cancer Bevacizumab Temsirolimus Phase II Charles Erlichman, MD
NCT00977574 Endometrial cancer Bevacizumab
Temsirolimus
Carboplatin
ixabepilone
Paclitaxel
temsirolimus
Phase II Carol Aghajanian, MD
NCT01005329 Endometrial cancer Bevacizumab
Carboplatin
Cisplatin Phase II Akila Viswanathan, MD
Paclitaxel
radiotherapy
NCT01367002 Uterine serous Trastuzumab Carboplatin
Paclitaxel Phase II Alessandro D Santin,
M.D.
NCT01256268 Endometrial Cancer Ridaforolimus Paclitaxel
Carboplatin Phase I Robert Wenham, M.D.
NCR01244438 Endometrial Cancer
with FGFR mutation FP-1039 / Phase II Sarah Thayer
NCT01065246 Epithelial
Carcinomas Catumaxomab Phase II Jalid Sehouli, MD
carboplatin was well tolerated in this patient population,
this study showed that this combination therapy failed to
demonstrateaprolongationofPFSwhencomparedwithhis-
torical data. In a GOG phase II trial, single agent cetuximab
demonstrated only minimal activity in patients with recur-
rent ovarian cancer with a response rate of 6.3% [62]. GOG
has also evaluated the eﬃcacy of cetuximab in the setting
of combination therapy with carboplatin in patients with
platinum-sensitive recurrent ovarian cancer. Results of this
trial showed only modest activity with a response rate of
34.5% [56].
Considering these results, further eﬀorts need to be car-
ried out in the direction of identifying markers that can pre-
dict response before cetuximab can become point of the
standard treatment.
4.3. EpCAM-Targeted Therapy: Catumaxomab. Catumax-
omab is the ﬁrst drug to be approved speciﬁcally for the
treatment of malignant ascites, thus becoming one of the
most successful monoclonal antibody to be employed in
oncology. The approval dates back to April 2009, when the
European Commission followed the recommendation of the
Committee for Human Medicinal Products (CHMP) and
approved catumaxomab for the i.p. treatment of malignant
ascites in patients with EpCAM+ carcinomas resistant to
standard treatments.
Catumaxomab (anti-EpCAM and anti-CD3) is a trifunc-
tional monoclonal antibody with two diﬀerent speciﬁcities,
which binds simultaneously to the EpCAM on tumour cells
and the CD3-antigen on T-cells. In addition, its Fc region
composed by the two Ig isotypes mouse IgG2a and rat IgG2b
selectively binds to human FcγI and III-receptors on innate
immune cells, such as macrophages, dendritic cells, and
NKs [63, 64]. Ertumaxomab (anti-HER2 x anti-CD3) is
another trifunctional monoclonal antibody diﬀering from
catumaxomab only because it binds to HER2 rather than
EpCAM [65].
Catumaxomab and ertumaxomab were ﬁrstly adminis-
tered intraperitoneally to eight patients with malignant
ascites (two of which with ovarian cancer) with the aim of
verifying their tolerability and biological and clinical effects
[29]. The two ovarian cancer patients were treated with
both catumaxomab and ertumaxomab at diﬀerent admin-
istration schedule. The ﬁrst ovarian cancer patient received
six administrations (ﬁve with catumaxomab and two with
ertumaxomab) during a 13-day period, whereas the other
patients were treated with ﬁve immunizations (ﬁve with
ertumaxomab only and the last one in combination with
catumaxomab). The treatment was well tolerated by all the
eight patients enrolled. Resolution of ascites was experienced
by all participants and seven out of eight participants did
not require further paracentesis during the follow-up, with
a median ascites-free interval of 38 weeks. As expected,
the resolution of ascites was correlated with elimination of
tumour cells (P<0.0014) as detected by FACS analysis and
immunocytochemistry. Complete elimination of EpCAM
and HER-2/neu tumour cells in ascites was obtained for
both ovarian cancer patients, that succumbed after 22 and
41 weeks, respectively.
Catumaxomab was also tested in a phase I/II dose-
escalating study on 23 women aﬀected by advanced ovar-
ian cancer with symptomatic malignant ascites containing
EpCAM+ tumour cells [63]. The participants were divided
into six diﬀerent groups and treated with four to ﬁve in-
traperitoneal catumaxomab in dose 5 to 200μgo nd a y s
0, 3, 6, 9, and 13. All patients were evaluated for toxicity,
clinical response, and immunological status. Serious adverse
events were detected in 15 out of 23 patients. In six patients
they were considered treatment-related. In the majority of
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observed after the third infusion, compared to baseline.
Twenty-two out of 23 patients did not require further para-
centesis after the last infusion, until the end of the study at
day37.TheresultsoftheprospectiverandomizedphaseII/III
study published by Heiss et al. in 2010 [66] conﬁrmed the
eﬃcacy of catumaxomab in the management of malignant
ascites. Two hundred and ﬁfty-eight patients aﬀected by
EpCAM+ epithelial tumor-related malignant ascites (129
recurrent ovarian cancer) were randomly assigned to receive
paracentesis followed by four i.p. infusion of catumaxomab,
in a ten-day period, or paracentesis alone. The Intention
to-Treat (ITT) analysis revealed that puncture-free survival
was signiﬁcantly longer in the catumaxomab group than
control group (46 versus 11 days; P<0.0001), as well
as the median time required for the next paracentesis (77
versus 13 days; P<0.0001). A positive trend in OS was
observed in the whole catumaxomab group and in the ovar-
ian cancer patients catumaxomab subgroup; furthermore
a signiﬁcant increase in OS was observed in the gastric
cancer patients catumaxomab subgroup. Catumaxomab-
related adverse events were manageable, reversible, and
associated to an acceptable safety proﬁle.
However, positive results were not reached by catu-
maxomab treatment in terms of tumor response. In fact,
the Phase IIa Study of the AGO Study Group revealed
that catumaxomab has modest activity in platinum-resistant
ovarian cancer, with only 5% of partial response being
obtained with high-dose catumaxumab [67].
4.4. Folate Receptor Alpha-Targeted Therapy: Farletuzumab.
Farletuzumab is a humanized MoAb with high aﬃnity for
folate receptor α (FRα). This receptor, almost absent in
normal tissue, is overexpressed in most ovarian cancers,
making it an attractive therapeutic target.
Preclinical studies have demonstrated that farletuzumab
mediates robust antibody-dependent cellular cytotoxicity
and complement-dependent cytotoxicity in vitro, inhibits
tumor growth in ovarian tumor xenografts, and displays a
safe toxicology proﬁle in not human primates [68, 69].
Farletuzumab has shown clinical eﬃcacy in early phase
trials as single agent and combination therapy with minimal
drug-speciﬁc toxicity [70].
The Phase III development plan in ovarian cancer
patients includes combination chemotherapy studies in
both platinum-sensitive (recently launched) and platinum-
resistant (planned) recurrent disease.
4.5. CA125-Targeted Therapy: Oregovomab. CA125 is a sur-
face mucin-like glycoprotein antigen that is expressed in
more than 95% of all not mucinous stage III/IV epithelial
ovarian cancers (EOCs) [71].
Serum CA125 level is a highly useful and well-established
surrogate for monitoring the response to treatment and a
useful marker during follow-up [72, 73].
Oregovomab is a MoAb against the tumour-associated
antigen CA125 as both membrane bound and soluble
forms. Oregovomab administration induces both cellular
and humoral multiepitope immune responses against the
tumor cells [74]. Based on the observation that ovarian
cancer patients, injected with this agent for diagnostic
purpose, showed prolonged survival [75], in 1998 the
immunological eﬀects of oregovomab were tested in 75
ovarian cancer patients [76]. All participants received from
one to ten injections of the MoAb and, after vaccinations,
64% of them developed anti-idiotypic antibodies against
oregovomab, whereas 24% developed anti-CA125 antibod-
ies. It was observed that these two types of antibody were
able to induce Fc-mediated tumour cell killing. Moreover, a
higher signiﬁcant survival was observed in patients in which
anti-CA125 antibody concentration increased more than 3-
foldafteroregovomabadministrations,comparedtopatients
without such increase. Furthermore, an improved overall
survival was observed also in patients who developed speciﬁc
anti-CA125 B- and T-cell response after oregovomab admin-
istration [77]. In 2004, Gordon et al. [78] vaccinated women
suﬀering from recurrent ovarian cancer with oregovomab.
Signiﬁcant increases in T-cell responses were measured in
7/18 (39%) patients in response to CA125, in 5/8 (63%)
patients in response to autologous tumor cells, and in
9/18 (50%) patients in response to oregovomab. Immune
responses appeared by week 12 (four doses) and were
generally maintained or augmented in patients maintaining
combined treatment with oregovomab and chemotherapy.
Median survival was 70.4 weeks (4.6–141.6 weeks), and the
median progression-free interval was 11 weeks (2.6–114.6
weeks). Patients who mounted a T-cell response to CA125
and/or autologous tumor showed signiﬁcantly improved
survival compared to patients who did not.
In2004, Bereketal.[79]enrolled145 patients aﬀectedby
advanced ovarian cancer (FIGO stage III-IV) in a random-
ized placebo-controlled study, to assess safety, feasibility, and
toxicity of oregovomab administration and to evaluate this
reagent as consolidation treatment. Unfortunately, despite a
benign safety proﬁle, Time to Relapse (TTR) was not signif-
icantly improved by consolidation therapy with oregovomab
(13.3 months oregovomab versus 10.3 months for placebo;
P = 0.71).
Oneyearlater,Ehlenetal.[80]showedimmuneandclin-
ical results of a pilot phase 2 study concerning oregovomab-
based vaccination in 13 patients with recurrent ovarian
cancer. Immune responses, including antibodies and T cells
to oregovomab and CA125, were demonstrated in more than
half of the patients. Disease stabilization and survival >2
years was observed in 3 of 13 patients and coincided with
robust immune responses. Shrinkage of marker lesions was
not observed; however, four patients showed decreases in
CA125 levels. Treatment was well tolerated without serious
adverse events. This pilot study supported immunologic
activity and safety of oregovomab in recurrent OC.
Long-term clinical results of this study were showed
in 2008 [81], after a 5-year follow-up. Patients assigned
to the oregovomab and placebo groups lived a median
of 57 and 48.6 months of progression-free survival (P =
0.276), respectively. Considering the time of survival after
relapse, oregovomab and placebo groups lived 31.2 and
20.7 months, respectively. Further analyses from this study
were recently reported [82]. A total of 371 patients wereClinical and Developmental Immunology 9
included in the study: 251 were treated with oregovomab
and 120 were assigned to the placebo group. After ﬁve
years, 169 and 80 patients belonging to the oregovomab and
placebo group, respectively, were still on treatment. It was
observedthatthemediantimetorelapsewas10.3monthsfor
oregovomab and 12.9 months for placebo-treated patients,
respectively. Survival data were not available at the time of
the report. The incidence of treatment adverse events was
similar in both groups. These data indicate that patients with
advanced ovarian cancer do not beneﬁt from oregovomab
maintenance monoimmunotherpy.
In 2009, a study assessing this immunotherapy at 2
dosingschedulesin40patientswithadvancedovariancancer
undergoing front-line carboplatin-paclitaxel chemotherapy
showed that combination of oregovomab immunotherapy
andchemotherapyexertedimmuneadjuvantproperties.The
possible combination of carboplatin and paclitaxel chemo-
therapy with oregovomab and other antigen-speciﬁc cancer
immunotherapy approaches should be further investigated.
Results obtained so far indicate that although CA125
remains an attractive target for immunotherapy, no eﬀective
clinical beneﬁt was observed by targeting this mucin.
4.6. MUC1-Targeted Therapy. MUC1 is a heavily glycosy-
lated transmembrane glycoprotein that is overexpressed in
many carcinomas [83, 84]. MUC1 consists of three domains
(a large extracellular motif, a transmembrane motif, and
a cytoplasmic tail) [85] and mediates signal transduction
events that stimulate the motility, invasion, and metastasis of
cancer cells. MUC1 is overexpressed on 90% of early ovarian
cancer cell surfaces [83]. In cancer patients, humoral and
cellularresponsesagainstMUC1havebeendetected[86,87].
Thus, MUC1 has been recognized as a promising molecular
target for immunotherapy in patients with ovarian cancer.
The mAb Human Milk Fat Globule 1 (HMFG1) is a
murine MoAb that recognizes an epitope localized in the
extracellular MUC1 domain.
In a ﬁrst phase I/II study, Yttrium-90-labeled HMFG1
alone or in combination with Yttrium-90-labeled MoAb
AUA1 (directed against an unspeciﬁed ovarian cell surface
antigen) was intraperitoneally administered to 25 patients
with advanced ovarian cancer, who previously had under-
gone cytoreductive surgery followed by chemotherapy [88].
Fourteen patients had assessable tumour at laparoscopy;
none of the three patients with tumour nodules greater than
2 centimetres diameter showed any response to treatment,
although one patients experienced resolution of her ascites.
One out of ten patients with tumour nodules less than 2
centimetres diameter had a partial response which persisted
for one year. Most frequent toxicities consisted in reversible
myelosuppression and thrombocytopenia.
Anextendedstudy[89]comparingradioimmunotherapy
(90Y-labeled HMFG1) after chemotherapy with chemother-
apy alone in 45 ovarian cancer patients, disease-free at
second-look laparoscopy, found that the active arm had
a signiﬁcantly higher OS (80%) at ﬁve-year follow-up, as
compared to the control group (50%).
Ten years later, a clinical study [90] carried out on 52
ovarian cancer patients (40% in complete clinical remission
and 60% with residual disease) revealed that a single intra-
peritoneal administration of 90Y-radiolabeled HMFG1 could
prolong long-term survival, with a 10-year survival rate of
70%.
In 2004, 26 women aﬀected by ovarian cancer received a
priming dose of 25mg of HMFG1 either intravenously (n =
10) or intraperitoneally (n = 16), followed by 6 intradermal
immunizations of HMFG1 in 10% Alhydrogel at 1-month
intervals [91]. The 3 dose levels were 0.5mg, 1mg, and 5mg.
Thirteen out of 26 patients completed the treatment, while
the other patients had clinical disease progression.
ELISA showed that all patients generated measurable
anti-idiotypic Ab (Ab2) after 3 immunizations, sustained at
1 month after the ﬁnal booster. No statistically signiﬁcant
diﬀerences were observed in the levels of Ab2 generated
by higher or lower booster doses or between patients
whose ﬁrst immunization was administered intravenously or
intraperitoneally. 5/13 patients (38%) increased anti-MUC1
levels above 0.015μg/mL (pretreatment peak). Ab3 (anti-
anti-idiotypic Ab) changes for the group as a whole were
not statistically signiﬁcant (P = 0.065). Furthermore, anti-
MUC1 levels did not correlate with Ab2 levels. Biosensor
assay, using the resonant mirror biosensor, showed no
diﬀerence in the aﬃnity of Ab2 generated by diﬀerent
booster doses of HMFG1. No clinical response was detected
in patients with measurable disease, although 1 patient
remainedwithoutclinicaldiseasefor5yearsaftercompletion
of vaccination.
The major study investigating safety and eﬃcacy of Y-
90-labeled HMFG1 [92] was carried out on 447 women
with FIGO stage IC to IV epithelial ovarian cancer in com-
plete remission of disease, surgically assessed through a
second-look laparoscopy. In this randomized control study,
224 patients were assigned to receive standard treatment
plus a single intraperitoneal infusion of 25mg Y-90-labeled
HMFG1, whereas 223 patients received standard treatment
alone. Clinical results showed that there was no signiﬁcant
diﬀerence in terms of OS (P = 0.4033) and PFS (P =
0.4764) between both groups, concordantly with time to
serological relapse (CA125 increase) (P = 0.3140). However,
it was observed [93] that signiﬁcantly fewer intraperitoneal
(P<0.05) and more extraperitoneal (P<0.05) relapses
occurred in patients who received Y-90-labeled HMFG1.
Furthermore, time to IP recurrence was signiﬁcantly (P =
0.0019) longer and time to extraperitoneal recurrence was
signiﬁcantlyshorter(P<0.001)fortheactivetreatmentarm.
Although serious adverse events occurred with no signiﬁcant
diﬀerences in both two arms, hematologic toxicities were
more frequent in the Y-90-labeled HMFG1, with a peak
incidence after the sixth week of treatment. Serum sample
from 208 patients in the active treatment group and 199
patients in the standard treatment group were evaluated
for anti-MUC1 IgG [94]. Anti-MUC1 IgG titers ranked
signiﬁcantly(P<0.001)higherintheactivetreatmentgroup
when tested at weeks 4, 8, and 12. A signiﬁcant diﬀerence
(P<0.001) in terms of median area under the curve (AUC)
between both groups was observed in favour of the active
treatment group. A signiﬁcant higher beneﬁt in OS and
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of the active treatment group with an anti-MUC1 IgG AUC
> 13 was shown by multivariate analysis and Kaplan-Mayer
analysis.
Recently, a humanized variant of the murine HMFG1,
AS1402, has been developed and is now being studied in a
phase II trial evaluating the eﬃcacy of the combination of
AS1402 with hormonal therapy in postmenopausal women
with advanced breast cancer [95]. This humanized antibody
could represent a potential treatment agent for patients with
ovarian cancer.
4.7. Targeting Immunesuppressive CTLA-4: Ipilimumab. Cy-
totoxic T lymphocyte-associated antigen 4 (CTLA-4) is a
surface ligand expressed by activated lymphocytes, which
binds to B7-1 and B7-2 ligand expressed upon APC
membrane for cell-cycle arrest and attenuation of eﬀector
function. Consequently, CTLA-4 acts as a negative regulator
of immune response. Ipilimumab is a humanized mono-
clonal antibody blocking CTLA-4, engineered to contrast the
negative immune regulation, thus increasing quantity and
duration of the immune eﬀector response against tumor
cells. Very recently, the results of signiﬁcant improvement
in overall survival obtained in melanoma setting [96]h a v e
led the FDA to approve ipilimumab in the treatment of
metastatic melanoma disease (http://www.fda.gov/,F D A
approval in August 2010), making the emergence of the key
role of CTLA-4 as a therapeutic target in oncologic patients
possible. Up to now, only one experience has been carried
out with ipilimumab in ovarian cancer.
In 2008 Hodi et al. [96] administered 1 to 11 infusions
ipilumimab in 9 patients with stage IV ovarian cancer and in
11 patients with metastatic melanoma. Each dose (3.0mg/kg
over 90 minutes) was administered at 2-3 months interval,
with the exception of 1 ovarian cancer who was treated
at 3- to 6-month intervals. Eligibility criteria included
previous vaccinations with irradiated, autologous tumor
cells engineered to secrete GM-CSF (GVAX). The most
relevant results involved 1 patient, who achieved a signiﬁcant
fall of CA125 levels several months after the ﬁrst dose of
ipilumimab. The antitumoral response did not involve the
generation of anti-CA125 Ab, but the increase in humoral
response against NY-ESO-1 was associated with therapeutic
eﬀects.
5. Monoclonal Antibodies in CervicalCancer
Currently no treatment with MoAbs has been authorized by
FDA for patients with cervical and endometrial malignancies
and therefore only experimental results are available.
In cervical cancer patients two molecules are currently
investigated as target for MoAbs-speciﬁc treatment: VEGF
and EGFR.
5.1. Vascular Endothelial Growth Factor. In cervical cancer
patients VEGF overexpression is associated with tumor
progression and poor prognosis [97, 98]; higher VEGF levels
appear to correlate with a more advanced disease stage and
increased risk of lymph nodes metastasis [99].
Furthermore, it has been shown that higher VEGF ex-
pression, as well as increased tumor vascularization, is inde-
pendent predictors of poor disease and OS [100].
Severalstudiesperformedonbevacizumab,usedassingle
agent or in association with other drugs, demonstrated that
this antibody is able to delay the progression of cervical
cancer [101, 102]. All patients received chemoradiation and
at least one other chemotherapy regimen prior to this com-
bination therapy withbevacizumab. After treatment,one pa-
tient achieved complete response, one partial response, and
two showed disease stabilizations. Furthermore we have
encouraging results on phase II multicenter trial to assess the
eﬃcacy and tolerability of bevacizumab used as single agent
in patients with persistent or recurrent squamous cervical
carcinoma.
Approximately, 24% of women beneﬁted from a pro-
gression free over 6 months and in 11% of patients a par-
tial response was observed [101]. The only phase III trial
withMoAbincervicalcancerisongoingnow[103](Table 4).
Results of this phase III trial are expected both for beva-
cizumab alone and in combination with chemotherapeutic
agents in recurrent/persistent or, mostly, stage IV cervical
cancer. In IV stage cervical cancer patients, a real standard
of care has not been well established nowadays [104].
Surgery, when technically feasible, intuitively appears as the
most direct way to eliminate tumour burden and overcome
radio and chemotherapy resistance caused by size in this
stage of disease. Unfortunately, several patients aﬀected by
large volume disease are considered inoperable. Neoadjuvant
chemotherapy (NACT) has demonstrated to increase the
proportion of women amenable of surgery and reduce
negative pathologic prognostic factors [105, 106]. Severe
prognosis is associated with this stage and the fact that
these patients are aﬀected by chemo-naive neoplasms makes
this setting of women particularly adequate to test new
combinations drug that include target therapies.
5.2. Epidermal Growth Factor Receptor. EGFR is tyrosine
kinase receptor of the family that includes HER2, HER3,
and HER4. This receptor mediates cell diﬀerentiation and
proliferation in both embryonic and adult tissues.
This receptor is overexpressed in approximately 85% of
invasivecervicaltumoursandisassociatedwithhigherstages
and poor prognosis [107–111]. Blockage experiments of this
receptorshowthatitexertsapositivemodulationofadjuvant
treatments.In particular,in human tumourxenograftin vivo
model MoAbs showed synergistic eﬀects with cisplatin and
doxorubicin [112] and in human this eﬀect was observed
with radiotherapy [57].
Between MoAb directed against EGFR, the ones that are
currently studied in cervical cancer patients are cetuximab
and matuzumab.
Cetuximab (Table 3) is a chimeric IgG1 mAb that antag-
onizes normal ligand receptor interactions and therefore
disrupts EGFR downstream signaling. The relation between
EGFR protein expression and response to mAb is doubtful,
as colorectal cancer patients without protein overexpression
may respond to cetuximab [113].Clinical and Developmental Immunology 11
Preclinical studies developed on cervical cancer cell lines
[114, 115] conﬁrm even in this tumor the results obtained
in murine model from Baselga group: both chemo and
radiotherapy join of cetuximab coadministration eﬀects
but apparently in a less EGFR-dependent way [115]. Less
encouraging are clinical results. No PFS and OS beneﬁts
have been registered in cervical cancer patients in either
advanced, recurrent, metastatic, or pretreated disease [116–
119]. However, better outcomes could result from an ongo-
ing clinical trial evaluating the addition of cetuximab to
standard treatment in patients with early stages of cervical
carcinoma.
6. Monoclonal Antibodiesin
EndometrialCancer
In endometrial cancer patients only VEGF is currently inves-
tigated as target for MoAbs-speciﬁc treatment. Therefore,
data on the possible role of Bevacizumab in endometrial
cancer are still scarce [120, 121].
6.1. Vascular Endothelial Growth Factor. VEGF is critical
for angiogenesis and tumor progression. Preliminary results
from studies conducted with the purpose of evaluating the
role of antiangiogenic agents in patients with endometrial
cancer are encouraging [121]. A study [120]o nr e c u r r e n t
or persistent endometrial cancer with bevacizumab showed
8/53 (15.1%) response rate, with 1 complete response and 7
partial responses. Median PFS was 4.2 months. Median OS
was 10.5 months. Several clinical trials are currently ongoing
(Table 5).
7. Discussion and Conclusion
Monoclonal antibodies have demonstrated to be eﬀective
in both hematologic and solid malignancies. This family
of antineoplastic agents have several diﬀerent mechanisms,
such as binding soluble ligands, blocking cell receptors, and
activating ADCC.
In ovarian cancer, encouraging results have been
observed with bevacizumab in ﬁrst and second line settings,
mostly in association to standard chemotherapy regimens.
Currently, the primary goal in combining bevacizumab to
standard chemotherapy is to test its eﬃcacy in increasing
the duration of ﬁrst remission. Preliminary results of ran-
domised trials carried out with this purpose seem to conﬁrm
a beneﬁt in terms of progression-free survival, whereas
data regarding overall survival remain currently less clear.
Furthermore, on the basis of the Japanese experience [122],
the GOG 262 is now testing the association between beva-
cizumab and paclitaxel in a dose dense front line regimen.
The rational of combining bevacizumab to weekly paclitaxel
in ﬁrst line setting dates back to recent evidences showing
that this association signiﬁcantly improves progression-free
survival in heavily pretreated recurrent epithelial ovarian
cancer [123, 124], thus conﬁrming the role of weekly
paclitaxel plus bevacizumab in synergistically inhibiting
angiogenesis [125].
As single agent in ovarian cancer palliative setting, cet-
uximab remains one of the most successful monoclonal
antibodies to be employed, with demonstrated and approved
high eﬃcacy in the management of ovarian cancer-related
malignant ascites. Another promising antibody, in gyneco-
logiconcology,seemstobefarletuzumab,targeting thefolate
receptor which is widely expressed by ovarian cancer cells.
Despitetherecognizedclinicalroleoftrastuzumab-based
therapy in breast cancer, current evidence seems to deny any
possible clinical relevance of single-agent trastuzumab-based
treatment both in ovarian cancer and in endometrial cancer
settings [126]. Studies assessing the association between
trastuzumab and standard chemotherapy regiments in these
types of gynecological malignancies are required.
Promising results have been currently obtained in ovar-
ian cancer setting by single-agent HMFG1 administration,
evenifstratiﬁcationoftheresultsintermsoftumorhistology
would clarify the most appropriate subset which can mostly
beneﬁt from anti-MUC1 vaccination. Clinical evaluation of
combining HMFG1 to chemotherapy is strongly needed.
Currently, no antibody has shown a particularly high
activity in cervical neoplasm. The high expression rate of
EGFR, targeted by cetuximab, makes this monoclonal anti-
body one of the most studied new drugs, even if some con-
cern has been raised for the tolerability of this drug in
previously irradiated patients. In ovarian cancer, this drug
revealed no positive clinical beneﬁt, both as single-agent
and in association to standard chemotherapy regimens. Fur-
thermore, its combination to chemotherapy seems to en-
hance the risk of treatment-associated adverse events, thus
discouraging future employment of this monoclonal anti-
body in this setting.
In endometrial cancer some experience has been gained
with bevacizumab. Results appear comparable to what ob-
served with nontarget drugs.
Up to now, target therapies have not been investigated
in rare gynecological malignancies such as vagina and vulvar
cancer.
Target therapies and in particular monoclonal antibodies
were introduced in oncology with the expectation of having
extremely favorable side eﬀects. On the contrary, hemotox-
icity, dermotoxicity, gastrointestinal toxicity, and high rates
of thromboembolic events have all been reported. With the
exception of bevacizumab, no target therapy has yet shown a
clear therapeutic eﬀect in gynecological malignancies.
Target therapies are in their infancy in gynecologic onco-
logy. The magnitude of their clinical impact is yet to be seen.
A crucial point that requires further investigations remains
to be patient selection and targets identiﬁcation.
MoAbs are destined to become an important tool in the
hands of oncologists that treat neoplasms of the genital tract
but, as all other established treatments, they will carry the
burden of a learning curve to manage their new side eﬀects.
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